Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy

Table 2 Analysis of the PSA response and the biochemical progression-free survival of patients treated with PSMA PET/CT-informed therapy, broken down by the sites of PSMA-avid relapses

Site	≥ 50% PSA response	One-way ANOVA P	Biochemical progression-free survival (mo)^a	HR (95% CI)	Log-rank P
Local relapse^b	12 (100.00%)	0.07	19.00 (10.00–23.00)	Reference	0.002
Pelvic nodal relapse^c	24 (75.00%)		19.50 (4.00–28.00)	1.89 (0.41–8.72)
Distant metastasis^d	9 (64.29%)		11.50 (4.00–22.00)	6.67 (1.45–30.63)

PSA Prostate-specific antigen; mo, months, HR hazard ratio, CI confidence interval
^aPresented as median (range)
^bMedian follow-up time of 19 mo (10–23 mo)
^cMedian follow-up time of 22 mo (8–32 mo)
^dMedian follow-up time of 20 mo (6–22 mo)

ISSN: 1470-7330